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Background: The purpose of the present study was to assess the trends in the use of ECV following published
studies that had compared rhythm and rate control strategies on atrial fibrillation (AF), and the recommendations
included in the current clinical practice guidelines.
Methods: The REVERCAT is a population-based assessment of the use of electrical cardioversion (ECV) in treating
persistent AF in Catalonia (Spain). The initial survey was conducted in 2003 and the follow-up in 2010.
Results: We observed a decrease of 9% in the absolute numbers of ECV performed (436 in 2003 vs. 397 in 2010).
This is equivalent to 27% when considering population increases over this period. The patients treated with ECV in
2010 were younger, had a lower prevalence of previous embolism, a higher prevalence of diabetes, and increased
body weight. Underlying heart disease factors indicated, in 2010, a higher proportion of NYHA≥ II and left
ventricular ejection fraction <30%. We observed a reduction in the number of ECV performed in 16 of the 27 (67%)
participating hospitals. However, there was an increase of 14% in the number of procedures performed in tertiary
hospitals, and was related to the increasing use of ECV as a bridge to AF ablation. Considering the initial number of
patients treated with ECV, the rate of sinus rhythm at 3 months was almost unchanged (58% in 2003 vs. 57% in
2010; p = 0.9) despite the greater use of biphasic energy in 2010 and a similar prescription of anti-arrhythmic drugs.
Conclusions: Although we observed a decrease in the number of ECVs performed over the 7 year period between
the two studies, this technique remains a common option for treating patients with persistent AF. The change in
the characteristics of candidate patients did not translate into better outcomes.
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The REVERCAT study (REgistre sobre la cardioVERSió
elèctrica a CATalunya; Registry of Electrical Cardiover-
sion in Catalonia) is a multi-center study involving 27
participating hospitals. The recording of characteristics
of electrical cardioversion (ECV) was intended to evalu-
ate the use of the technique in patients with atrial fibril-
lation (AF) in current clinical practice in Catalonia
(Spain). The initial study was conducted at the start of* Correspondence: txalegret@hotmail.com
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reproduction in any medium, provided the or2003. The current re-evaluation was conducted early in
2010 and, over these past 7 years, there have been a few
studies published, and subsequent guidelines generated,
which described the lack of a clear benefit of rhythm con-
trol vs. rate control strategies in patients with AF [1-3].
The purpose of the present study was to compare the fre-
quency and characteristics of patients treated with ECV
between the years 2003 and 2010; the objective being to
assess the impact of major clinical trials and recommenda-
tions included in the current clinical practice guidelines.Methods
The REVERCAT study was set-up to record, prospect-
ively, all patients with persistent AF who wereLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pating hospitals which are representative of the whole of
Catalonia (an Autonomous Community in NE Spain)
(Table 1).
The area of Catalonia is 31,930 km2 and the popula-
tion was 6,506,000 inhabitants in 2003 and 7,512,000
inhabitants in 2010, all of whom have the right to
health-care provision under the publicly-funded
National Health Service. The hospitals participating in
the present study attend to approximately 90% of this
population. The initial registry was set-up between 1st
February and 30th October 2003. The present study was
conducted between 1st February and 30th October 2010,
the purpose being to assess the changes in the use of
ECV in clinical practice in Catalonia. The patients
included in the study to have ECV applied were all those
who met the criteria of being ≥18 years of age, with AFTable 1 List of investigators and centers participating in
the REVERCAT study
Clinical Investigatora Affiliation
X Sabaté H.U. de Bellvitge, Hospitalet de Llobregat
R Serrat H del Mar
A Sualís H de Mataró
F Planas H. de Badalona
G Vazquez H. Comarcal de la Selva, Blanes
J Escudero H Mútua de Terrassa
X Abardia/C Barberà Clínica Ponent, Lleida
L Guillamon H. Parc Taulí, Sabadell
L Mont/N Calvo H. Clínic, Barcelona
J Sadurní H. General de Vic
S Pons H de Barcelona
A Descalzi H. Comarcal Alt Penedés, Vilafranca del Penedés
N Batalla H. Sagrat Cor, Barcelona
E Sanz/S Serrano H.U. Joan XXIII, Tarragona
J Pérez-Rodon H.G.U. Vall d’ Hebrón, Barcelona
E Rodríguez-Font H. Sta Creu i Sant Pau, Barcelona
F Freire H. de Palamós, Palamós
M Vilaseca H de Calella, Calella
C Romero H. Sant Boi de Llobregat
I Duran H.U. Sant Joan de Reus
J Tomàs H.U. Arnau de Vilanova, Lleida
I Lechuga H. Verge de la Cinta, Tortosa
R Villuendas H. Germans Trias i Pujol, Badalona
A Jaber H. de Terrassa
I Romeo H. d’Igualada
R Canals H. Comarcal de Mollet
M Paz H de Figueras
aCollaborators in Pubmed.duration >7 days, and with no precipitating conditions
including hyperthyroidism, fever, cardiac surgery and
pericarditis. Successful ECV was considered when sinus
rhythm (SR) was achieved, and excluded patients with
immediate relapse. A clinical and ECG follow-up was
performed at 3 months post-ECV. Patients were consid-
ered to have maintained SR at 3 months if there had not
been a relapse of persistent AF and, as well, the ECG at
3 months of follow-up showed SR. The information
recorded included clinical data, treatment, echocardiog-
raphy data, and procedure variables. We compared all
these variables in the two surveys conducted 7 years
apart. The principal investigator in each hospital was the
same in both surveys in 21 of the 27 participating
hospitals.
The study received approval from the Institutional
Review Boards (Clinical Ethics Committee) of each par-
ticipating hospital on the understanding that the data were
coded on entry into the registry and that patient privacy
was respected. Written informed consent was obtained
from the patient for publication of this report.
Statistical analyses
Qualitative variables are expressed in percentages, and
the differences assessed using the chi-squared test.
Quantitative variables are presented as means ± standard
deviation (SD) and the differences between means evalu-
ated using the Student t-test. Statistical significance was
accepted at p values <0.05. All analyses were performed
with the SPSS statistical software package (version 18).
Results
There were 397 ECVs performed in 2010 compared to
436 in 2003. These were consecutive patients meeting
the inclusion criteria and having ECV performed over
the same period of the year-of-study (February to October).
This represents a 9% reduction in the number of proce-
dures which, when taking into account the increase in the
catchment population between 2003 and 2010, represents
a reduction of 27%.
The clinical characteristics are summarized in Table 2.
The patients treated with ECV in 2010 had a lower
mean age, a lower prevalence of prior embolism, a
higher prevalence of diabetes and a higher mean body
weight compared to those treated with ECV in 2003.
With respect to the underlying heart disease, in 2010
we observed a higher proportion of NYHA≥ II, lower
mean ejection fraction, and a higher prevalence of
EF <30% than in 2003.
There was a reduction in the numbers of patients in
whom ECV was applied in 16 of 27 (67%) participating
hospitals. However, the distributions of the treatment
indicated a higher number of ECV procedures in
tertiary-care hospitals (mainly university-associated)
Table 2 Comparisons of the clinical and
echocardiographic characteristics of patients included in











Age; years 65 ± 11 64 ± 11 0.03
Age; >70 years 170 (39) 119 (30) 0.008
Male gender 296 (68) 285 (72) 0.19
Weight; kg 78.2 ± 13 80.9 ± 14 0.01
Height; cm 167 ± 9 168 ± 9 0.14
Body surface area; m2 1.86 ± 0.19 1.90 ± 0.19 0.006
Hypertension 222 (51) 222 (56) 0.14
Diabetes mellitus 57 (13) 75 (19) 0.04
Previous embolism 46 (12) 29 (7) 0.02
NYHA Class≥ II 135 (31) 175 (44) 0.0001
Left atrial size 45.4±6.3 45.4±6.8 0.95
Left atrial dilatation
(>50mm)
61 (14) 67 (17) 0.42
Left ventricular
hypertrophy
113 (26) 119 (30) 0.21
LVEF (%) 58 ± 14 56 ± 14 0.02
LVEF <30% 8 (2) 19 (5) 0.05
Previous electrical
cardioversion
65 (15) 87 (22) 0.009
Duration of AF >1 year 48 (11) 59 (15) 0.35
Anti-arrhythmic drugs 327(78) 296 (76) 0.39
Amiodarone: 268 (64) 247 (62)
Ic: 39 (9) 32 (9)
Sotalol: 9 (2) 5 (1)
Others: 11 (3) 12 (3)
ACE inhibitor/ARB 197 (45) 197 (50) 0.12
*AF: atrial fibrillation; LVEF: left ventricular ejection fraction; Ic: flecainide,
propafenone; ACE: angiotensin-converting enzyme; ARB: angiotensin receptor
blockers.
Table 3 Electrical cardioversion procedure characteristics










Use of biphasic energy 70 (16) 349 (88) <0.001
Successful ECV (overall) 374 (86) 355 (89) 0.21
- Monophasic energy 313 (85) 42 (87) 0.69
- Biphasic energy 61 (89) 313 (90) 0.90
Number of shocks (overall) 1.73 ± 0.9 1.5 ± 0.9 0.0001
- Monophasic shocks 1.76 ± 0.9 1.70 ± 0.83 0.90
- Biphasic shocks 1.61 ± 0.86 1.45 ± 0.78 0.07
Energy delivered (overall) (J) 239 ± 90 165 ± 63 0.0001
- Monophasic shocks 253 ± 77 234 ± 81 0.11
- Biphasic shocks 166 ± 95 154 ± 51 0.48
*ECV: electrical cardioversion; J: Joules.
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2010. In 2003 the district hospitals accounted for 57% of
procedures compared to 43% in the tertiary hospitals. In
2010 the district hospitals performed 47% of the proce-
dures compared to 53% in tertiary hospitals (p = 0.004).
Between 2003 and 2010, we observed an absolute
decrease of 23% (p = 0.004) in the number of ECVs per-
formed in district hospitals (247 in 2003 vs. 189 in
2010). Conversely, there was an absolute increase in the
use of ECV in tertiary hospitals of 14% (p = 0.004) in
2010 (189 in 2003 vs. 208 in 2010). There were 7
patients in 2003 in whom ECV was applied as a bridge
to AF ablation. In 2010 the number increased to 36; 3
centers performing AF ablations in 2003, and 5 centersin 2010. Overall, the numbers of AF ablations performed
in the two periods of the study were 30 in 2003 and 129
in 2010.
The ECV success rates were similar in 2003 and 2010
(86% in 2003 vs. 89% in 2010; p = 0.21), despite the more
frequent use of biphasic energy in 2010 (16% in 2003
vs. 88% in 2010; p = 0.0001) (Table 3).
The use of anti-arrhythmic drugs pre-ECV and at dis-
charge from hospital was also similar in both surveys (pre-
ECV 73% in 2003 vs. 68% in 2010; p = 0.26; at discharge
78% in 2003 vs. 76% in 2010; p = 0.39). Amiodarone was
the preferred drug in both studies. It was used in 64% of
patients in 2003 vs. 62% of patients in 2010 (p= 0.62),
independently of underlying left ventricular ejection frac-
tion. Dronedarone was not available in Spain until the end
of the 2010 study.
With respect to anticoagulation treatment, the con-
ventional use of coumarins at least 3 weeks pre- and
1 month post-ECV was the most common pattern (2003
59% vs. 2010 61%; p = 0.75). The rate of patients requir-
ing chronic anticoagulant therapy prior to the decision
to perform ECV was similar (27% in 2003 vs. 30% in
2010; p = 0.67), whereas the use of transesophageal echo-
cardiography with short patterns of anticoagulation (5%
in 2003 vs. 7% in 2010; p = 0.65) and other patterns (9%
in 2003 vs. 2% in 2010, p = 0.28) were very low in both
surveys.
The rate of SR was similar in both surveys at 3 months
of follow-up (67% in 2003 vs. 64% in 2010; p = 0.21). If
we considered the patients with and without anti-
arrhythmic drugs at discharge from hospital, the rates of
SR at 3 months were also similar. The patients receiving
anti-arrhythmic medications in 2003 accounted for 70%
of the total compared to 68% in 2010 (p = 0.30). Patients
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accounted for 58% of the total compared to 55% in 2010
(p = 0.59). Of those treated with ECV, the rate of patients
in whom the SR was restored and maintained at
3 months was almost unchanged in the two periods of
the study (58% in 2003 vs. 57% in 2010; p = 0.9).
Discussion
To the best of our knowledge this is the first population-
based study that analyzed the treatment of AF over time,
specifically the use of ECV. Also, this was an opportun-
ity to observe the impact in clinical practice of new evi-
dence reflected in guideline recommendations. We
observed that between 2003 and 2010 there was a reduc-
tion in the number of ECVs performed and a change in
the characteristics of patients treated i.e. this finding
may be related to a lower use of the rhythm control
strategy compared to rate control in the population with
the current characteristics . However, ECV continues to
be used frequently in clinical practice.
The AFFIRM and RACE trials [1,2] demonstrated no
differences in terms of morbido-mortality when compar-
ing rate vs. rhythm control strategies in patients with
AF. Also the AF-CHF trial [4], focusing on patients with
heart failure or left ventricular dysfunction, observed no
difference in cardiovascular mortality. Prior to this evi-
dence, it was accepted in clinical practice that the relief
of symptoms as well as prevention of embolism and
avoidance of cardiomyopathy (theoretically adding to the
maintenance of SR) could be reasons for restoration of
SR. These consensus opinions are reflected in the guide-
lines from the ESC/AHA/ACC 2001 [5]. Subsequent to
these publications, the concept became accepted that
anticoagulation should not be stopped despite the res-
toration of SR in patients with criteria for anticoagula-
tion. Thus, in the 2006 ESC/AHA/ACC guidelines, the
avoidance of long-term anticoagulation was not consid-
ered a reason for ECV [3]. The recent ESC 2010 guide-
lines [6] were published in the course of the conduct of
the present study, as were the ACCF/AHA/HRS 2011
guidelines [7] which were published soon after the
study’s completion. These guidelines support anticoagu-
lation maintenance (if the patient fulfills the criteria for
anticoagulation) despite the patient achieving SR. Thus,
guidelines limit the recommendations for ECV to
patients with clear symptoms related to AF, without any
intention to reduce morbido-mortality. Theoretically,
this would imply a reduction in the number of ECVs
performed. However, there is scant information regard-
ing the influence of these guidelines on the use of ECV
[8] and, perhaps more importantly, the characteristics of
patients who are candidates for treatment with ECV.
Our initial survey was begun in early 2003, a short time
after the publication of the AFFIRM and RACE studiesin December 2002, the findings of which are consistent
with our findings in 2010. Although we observed a con-
siderable decrease in the number of ECVs performed,
this technique remains a common option for treating
patients with AF. This may be related to the impression
that, when the data from these trials are analyzed
according to the patient’s actual rhythm, the benefit of
SR over AF becomes apparent [9]. A more profound
analysis of AFFIRM study reveals several limitations that
preclude the assumption that attempting to restore SR is
not worthwhile i.e. the study had a low percentage of SR
patients in the rhythm control group, low efficacy and
increased risk of death of AAD, a high percentage of SR
patients in the rate control group, lower use of beta-
blockers in rhythm control group, and exclusion of
patients with severe symptoms who would, potentially,
most benefit from SR. Strictly, the study should not be
interpreted as a comparison of SR vs. AF and, indeed,
may reflect the ineffectiveness of the rhythm control
methods used.
From our results we may deduce a change in the indica-
tions for ECV. Current patients are more symptomatic for
heart failure, and with higher disease burden. We also
noted that in the 2003 survey the patients were less symp-
tomatic for heart failure, were older and with higher preva-
lence of previous embolism. This would suggest that,
currently, the avoidance of long-term anticoagulation is
not considered an indication for a rhythm control strategy
in slightly symptomatic patients with criteria for anticoagu-
lation. Although other factors may be contributing to these
findings, the suggestion is that such publications may have
had a significant influence on our standard clinical
practice.
We note a reluctance towards the use of transesopha-
geal echocardiogram (TEE) in the ECV procedure in
both of our surveys that had been conducted 7 years
apart. The publication of the ACUTE study [10] in 2001
negated the expectations that TEE could reduce embo-
lisms and complications related to anticoagulation, as
well as improve the efficacy of ECV because of the
shorter time-lapse between the indication and the ECV.
Both of our evaluations reflect the few occasions in
which this technique may be useful in standard clinical
practice. Conversely, we observed almost a complete
substitution of monophasic energy (the more frequent
option in 2003) for biphasic energy which was used in
2010, and which had been recommended in the 2006
guidelines. The use of biphasic source results in fewer
skin lesions and greater rate of reversion to SR for the
same amount of energy administered [11,12]. Also, max-
imum biphasic energy shock is useful, especially in
patients with greater body surface area [13]. The slightly
higher efficacy of ECV in our 2nd survey of 2010 would
be attributable to the use of biphasic energy. However,
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in patients’ characteristics did not result in a higher rate
of SR at 3 months of follow-up. Biphasic energy could
benefit a patient with a profile of higher probability of
AF relapse due to higher body mass index [14]. The use
of anti-arrhythmic drugs was relatively high and similar
in both surveys. Although its use was related to better
rates of SR at 3 months of follow-up, its efficacy was
relatively low. The introduction of new anti-arrhythmic
drugs with higher efficacy and less adverse effects should
help to improve these outcomes in the near future.
Around half of the patients had been treated with
ACE inhibitors/angiotensin receptor blockers (most of
them for hypertension), without significant differences
between both registries. The benefit of these drugs in
the prophylaxis of AF relapse post-ECV has been
clear in the published studies [15,16] and this is
reflected in the 2001 and 2006 ESC/AHA/ACC guide-
lines as well as the 2010 ESC guidelines, which do
not recommend its use.
Of interest is the change in the number of ECVs per-
formed in tertiary (referral) hospitals versus district (gen-
eral) hospitals. Overall, in the district hospitals we
observed a clear decrease in the number of ECVs per-
formed while, in tertiary hospitals, there was an increase.
The introduction of catheter ablation may explain these
findings, with the use of ECV as a bridge to ablation. As
mentioned earlier, this reflects the interest in the rhythm
control strategy if there are appropriate therapeutic mea-
sures that impact on effective SR maintenance.
Our study has some limitations. One of them is the
lack of information on the total number of patients with
AF attended-to in our clinics. In consequence, we can-
not strictly affirm that there has been a decrease in the
proportion of patients treated with rhythm vs. rate con-
trol strategy. However, if we assess the increasing preva-
lence of AF [17,18] related, above all, to aging we may
deduce a decrease in the proportion of patients with AF
treated with the rhythm control strategy; the proportion
probably being higher than that indicated by the de-
crease in the number of ECV that we observed. In our
population the mean age increased from 45.8 to 47 years
and the number of people >60 years of age increased by
14% during this period. Another limitation of our study
is the lack of information on symptoms strictly related
to AF. Symptoms described in our study only related to
heart failure. A scale of symptoms related to AF had
been proposed in 2007 by the EHRA [19] and was
included in the 2010 ESC guidelines. As such, it had not
been available at the time of our first survey performed
in 2003. However, we believe that the attempt to relieve,
or improve, symptoms of heart failure may be consid-
ered when an ECV is indicated, as had been assessed in
our survey.Conclusions
In conclusion, we observed that ECV technique con-
tinues to be used widely as treatment for patients with
AF; albeit applied to candidate patients with different
characteristics.
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